Gennova Biopharmaceuticals,a 100% vertically integrated arm of Emcure Pharmaceuticals Limited based out of Pune announced the commercial launch of indigenously developed PEGEX (Pegfilgrastim) in India. PEGEX (Pegfilgrastim) is indicated to reduce the duration of Neutropenia and also the incidence of febrile Neutropenia in patients treated with cytotoxic chemotherapy for treatment of cancer. The cost of PEGEX(Pegfilgrastim) is Rs.17,900/- to the patient which is the most economical brand as compared to other pegfilgrastim brands which are currently priced above Rs. 27,000 Talking about Gennova Biopharmaceuticals,CEO Dr. Sanjay Singh said,Our scientists have developed Elaxim,the only biosimilar tenectaplase available today. This drug is used in the management of myocardial infarction with S/T segment elevation. It has been used in 11,000 patients in India,and data from 2100 such patients are published in peer-reviewed journals. With the launch of PEGEX (Pegfilgrastim),Gennova is fulfilling its mission of offering cost effective high end technology medicines produced in India. Speaking on the occasion of the launch of PEGEX(Pegfilgrastim),Arun Khanna,COO of Emcure Pharmaceuticals said Cytotoxic chemotherapy induced neutropenia is often identified in 10 - 57% of patients and with certain chemotherapy regimens the risk of febrile neutropenia is more than 20%. Old age and other co-morbid conditions can also increase the risk of Febrile Neutropenia.
